These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38359001)

  • 1. Assessment of potential transthyretin amyloid cardiomyopathy cases in the Brazilian public health system using a machine learning model.
    Zuppo Laper I; Camacho-Hubner C; Vansan Ferreira R; Leite Bertoli de Souza C; Simões MV; Fernandes F; de Barros Correia E; de Jesus Lopes de Abreu A; Silva Julian G
    PLoS One; 2024; 19(2):e0278738. PubMed ID: 38359001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis.
    Patel RK; Ioannou A; Razvi Y; Chacko L; Venneri L; Bandera F; Knight D; Kotecha T; Martinez-Naharro A; Masi A; Porcari A; Brown J; Patel K; Manisty C; Moon J; Rowczenio D; Gilbertson JA; Sinagra G; Lachmann H; Wechalekar A; Petrie A; Whelan C; Hawkins PN; Gillmore JD; Fontana M
    Eur J Heart Fail; 2022 Dec; 24(12):2355-2363. PubMed ID: 36575133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
    Antonopoulos AS; Panagiotopoulos I; Kouroutzoglou A; Koutsis G; Toskas P; Lazaros G; Toutouzas K; Tousoulis D; Tsioufis K; Vlachopoulos C
    Eur J Heart Fail; 2022 Sep; 24(9):1677-1696. PubMed ID: 35730461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving epidemiology of transthyretin amyloid cardiomyopathy due to increased recognition in women.
    Prasad M; Kim M; Chandrashekar P; Zhao Y; Fischer KL; Nazer B; Masri A
    Int J Cardiol; 2023 Mar; 374():116-119. PubMed ID: 36587655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.
    Donnellan E; Wazni OM; Saliba WI; Hanna M; Kanj M; Patel DR; Wilner B; Kochar A; Jaber WA
    Am J Cardiol; 2020 Aug; 128():140-146. PubMed ID: 32650908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, clinical characteristics, and diagnostic approach in transthyretin amyloid cardiomyopathy: The Kumamoto Cardiac Amyloidosis Survey.
    Takashio S; Tokitsu T; Matsukawa M; Sakaino N; Fujimoto K; Sakamoto T; Noda K; Tsunoda R; Misumi I; Hirai N; Doi H; Koide S; Mizuno Y; Hirose T; Kurokawa H; Kajiwara I; Ohba K; Miyamoto S; Araki S; Yamamoto E; Matsushita K; Ueda M; Tsujita K;
    J Cardiol; 2022 Jul; 80(1):49-55. PubMed ID: 35078683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden.
    Lauppe RE; Liseth Hansen J; Gerdesköld C; Rozenbaum MH; Strand AM; Vakevainen M; Kuusisto J; Gude E; Gustafsson F; Smith JG
    Open Heart; 2021 Oct; 8(2):. PubMed ID: 34645699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases.
    Damy T; Bourel G; Slama M; Algalarrondo V; Lairez O; Fournier P; Costa J; Pelcot F; Farrugia A; Zaleski ID; Lilliu H; Rault C; Bartoli M; Fievez S; Granghaud A; Rudant J; Coste A; Cosson CN; Squara PA; Narbeburu M; De Neuville B; Charron P
    Orphanet J Rare Dis; 2023 Nov; 18(1):345. PubMed ID: 37926810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary Transthyretin Amyloidosis Cardiomyopathy: The South Florida Experience.
    Trujillo L; Colombo R
    Am J Cardiol; 2022 Oct; 180():140-148. PubMed ID: 35945038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy.
    Castaño A; Heitner SB; Masri A; Huda A; Calambur V; Bruno M; Schumacher J; Emir B; Isherwood C; Shah SJ
    J Card Fail; 2024 Jun; 30(6):778-787. PubMed ID: 38065306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.
    Ruberg FL; Grogan M; Hanna M; Kelly JW; Maurer MS
    J Am Coll Cardiol; 2019 Jun; 73(22):2872-2891. PubMed ID: 31171094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis.
    Chacko L; Martone R; Bandera F; Lane T; Martinez-Naharro A; Boldrini M; Rezk T; Whelan C; Quarta C; Rowczenio D; Gilbertson JA; Wongwarawipat T; Lachmann H; Wechalekar A; Sachchithanantham S; Mahmood S; Marcucci R; Knight D; Hutt D; Moon J; Petrie A; Cappelli F; Guazzi M; Hawkins PN; Gillmore JD; Fontana M
    Eur Heart J; 2020 Apr; 41(14):1439-1447. PubMed ID: 31950987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare resource use of patients with transthyretin amyloid cardiomyopathy.
    Lauppe R; Liseth Hansen J; Fornwall A; Johansson K; Rozenbaum MH; Strand AM; Vakevainen M; Kuusisto J; Gude E; Smith JG; Gustafsson F
    ESC Heart Fail; 2022 Jun; 9(3):1636-1642. PubMed ID: 35365974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vutrisiran: First Approval.
    Keam SJ
    Drugs; 2022 Sep; 82(13):1419-1425. PubMed ID: 35997942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.
    Lane T; Fontana M; Martinez-Naharro A; Quarta CC; Whelan CJ; Petrie A; Rowczenio DM; Gilbertson JA; Hutt DF; Rezk T; Strehina SG; Caringal-Galima J; Manwani R; Sharpley FA; Wechalekar AD; Lachmann HJ; Mahmood S; Sachchithanantham S; Drage EPS; Jenner HD; McDonald R; Bertolli O; Calleja A; Hawkins PN; Gillmore JD
    Circulation; 2019 Jul; 140(1):16-26. PubMed ID: 31109193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage.
    Law S; Petrie A; Chacko L; Cohen OC; Ravichandran S; Gilbertson JA; Rowczenio D; Wechalekar A; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Fontana M; Gillmore JD
    ESC Heart Fail; 2020 Dec; 7(6):3942-3949. PubMed ID: 32924285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.